DONG-E-E-JIAO CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.47 CNY | +0.40% |
|
+6.11% | +40.86% |
| Apr. 12 | Dong-E-E-Jiao Forecasts Up to 55% Jump in Q1 Profit | MT |
| Mar. 22 | Dong-E-E-Jiao's Profit Jumps 47.6% in 2023 | MT |
| Sales 2024 * | 5.59B 772M | Sales 2025 * | 6.47B 894M | Capitalization | 44.74B 6.18B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.39B 192M | Net income 2025 * | 1.62B 223M | EV / Sales 2024 * | 7.16 x |
| Net cash position 2024 * | 4.73B 654M | Net cash position 2025 * | 5.11B 706M | EV / Sales 2025 * | 6.12 x |
| P/E ratio 2024 * |
32.2
x | P/E ratio 2025 * |
27.8
x | Employees | 3,678 |
| Yield 2024 * |
2.87% | Yield 2025 * |
2.79% | Free-Float | 66.22% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.40% | ||
| 1 week | +6.11% | ||
| Current month | +12.92% | ||
| 1 month | +13.11% | ||
| 3 months | +35.82% | ||
| 6 months | +49.56% | ||
| Current year | +40.86% |
1 week
64.86
70.13
1 month
58.6970.13
Current year
47.3870.13
1 year
44.5270.13
3 years
27.6070.13
5 years
24.9270.13
10 years
24.9273.71
| Managers | Title | Age | Since |
|---|---|---|---|
Jie Cheng
PSD | President | 45 | 22-01-09 |
Hong Yan Ding
DFI | Director of Finance/CFO | 54 | 21-06-28 |
Rong Deng
BRD | Director/Board Member | 46 | 20-03-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guang Li Liu
BRD | Director/Board Member | 60 | 08-06-29 |
De An Guo
BRD | Director/Board Member | 62 | 21-06-28 |
Ran Tao
CHM | Chairman | 59 | 19-08-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.48% | 2 M€ | -20.87% | - | |
| 0.11% | 1 M€ | +3.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 69.47 | +0.40% | 4 836 805 |
| 24-04-18 | 69.19 | +2.31% | 5,965,703 |
| 24-04-17 | 67.63 | +0.27% | 4,859,578 |
| 24-04-16 | 67.45 | +0.91% | 6,995,887 |
| 24-04-15 | 66.84 | +2.05% | 5,245,372 |
End-of-day quote Shenzhen S.E., April 18, 2024
More quotes
Dong-E-E-Jiao Co., Ltd. specializes in the manufacturing and marketing of Chinese traditional medicines and health products. The products are primarily for deficiencies in the blood, immunodeficiency, indigestion, insomnia and fatigue.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
69.47
CNY
Average target price
67.94
CNY
Spread / Average Target
-2.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.86% | 6.16B | |
| -16.30% | 4.49B | |
| -9.93% | 3.17B | |
| -1.58% | 3.01B | |
| -1.70% | 2.57B | |
| +37.23% | 1.8B | |
| -12.78% | 1.62B | |
| +1.02% | 1.56B | |
| -12.97% | 1.53B | |
| +36.02% | 1.29B |
- Stock Market
- Equities
- 000423 Stock
